Clinical trial
A Phase 1/2 Study of Antisense Oligonucleotide Therapy for Treatment of Ataxia-Telangiectasia
NCT07215416 is registered in ClinicalTrials.gov with Timothy Yu as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Study of Antisense Oligonucleotide Therapy for Treatment of Ataxia-Telangiectasia
- Lead sponsor
- Timothy Yu
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- August 31, 2026
- Completion date
- December 31, 2036
- Enrollment
- 10 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.